Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may spot hidden bleeding in heart attacks

NCT ID NCT05872308

Diagnosis Sponsor: Rohan Dharmakumar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested whether a common blood test for troponin, a heart damage marker, can tell if a heart attack involves bleeding in the heart muscle. Researchers measured troponin levels in 227 patients after they had a heart attack and compared those with and without bleeding seen on MRI. The goal is to develop a non-invasive way to detect hemorrhagic myocardial infarction, which may require different treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to identify which heart attack patients have bleeding in the heart, guiding more personalized treatment.
What could go wrong
This is a small, completed pilot study. The findings need confirmation in larger trials before changing clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

227 people

The number who actually took part.

Started

Jul 2022

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of individuals aged 18 to 80 who have been diagnosed with acute ST-elevation myocardial infarction (STEMI) and are scheduled for emergency percutaneous coronary intervention (PCI).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years 2. Index STEMI 3. Coronary angiogram with PCI to occur irrespective of the onset of the symptoms. 4. Ability to provide informed consent for themselves Exclusion Criteria: 1. History of prior myocardial infarction, 2. Cardiogenic shock, 3. Patients who present with current cardiac arrest 4. Any contraindication to cardiac CMR (claustrophobia, pacemaker or cardiac defibrillator, known allergy to gadolinium), 5. Presence of permanent atrial fibrillation, 6. Unconscious patient, 7. Severe renal insufficiency (creatinine clearance ≤ 30 ml/min/m2 or renal replacement therapy), 8. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction

Contacts and locations

Locations

  • IU Methodist Hospital

    Indianapolis, Indiana, 46202, United States

  • Synergy Cardiovascular Research Center, Synergy Superspecialty Hospital

    Rajkot, Gujarat, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.